|
|
||||||||||
|
J Am Coll Cardiol, 2003; 41:1438-1444, doi:10.1016/S0735-1097(03)00241-9 © 2003 by the American College of Cardiology Foundation |


* Division of Cardiology, Second University of Naples, Naples, Italy
Fresenius Medical Care-Italia, Naples-NephroCare Group, Naples, Italy
Department of Internal Medicine, University Federico II, Naples, Italy
Manuscript received June 23, 2002; revised manuscript received November 25, 2002, accepted November 27, 2002.
* Reprint requests and correspondence: Dr. Gennaro Cice, Division of Cardiology, Second University of Naples, Piazza L, Miraglia, 2-80138 Naples, Italy.
gennarocice{at}hotmail.com
OBJECTIVES: We sought to evaluate the effects of carvedilol on mortality and morbidity in dialysis patients with dilated cardiomyopathy.
BACKGROUND: Several lines of evidence support the concept that therapy with beta-blocking agents reduces morbidity and mortality in patients with congestive heart failure (HF), but the demonstration of such a survival benefit in dialysis patients with dilated cardiomyopathy is still lacking.
METHODS: A total of 114 dialysis patients with dilated cardiomyopathy were randomized to receive either carvedilol or placebo in addition to standard therapy. A first analysis was performed at one year and was followed by an additional follow-up period of 12 months.
RESULTS: Two-year echocardiographic data revealed a significant attenuation of pathologic remodeling, with smaller cavity diameters and higher ejection fractions in the active treatment group than in the placebo group. At two years, 51.7% of the patients died in the carvedilol group, compared with 73.2% in the placebo group (p < 0.01). Furthermore, there were significantly fewer cardiovascular deaths (29.3%) and hospital admissions (34.5%) among patients receiving carvedilol than among those receiving a placebo (67.9% and 58.9%, respectively; p < 0.00001). The exploratory analyses revealed that fatal myocardial infarctions, fatal strokes, and hospital admissions for worsening HF were lower in the carvedilol group than in the placebo group. A reduction in sudden deaths and pump-failure deaths was also observed, though it did not reach statistical significance.
CONCLUSIONS: Carvedilol reduced morbidity and mortality in dialysis patients with dilated cardiomyopathy. These data suggest the use of carvedilol in all dialysis patients with chronic HF.
| ||||||||||||||||||||||||||||||
This article has been cited by other articles:
![]() |
N. Johnston, H. Dargie, and A. Jardine Diagnosis and treatment of coronary artery disease in patients with chronic kidney disease Heart, August 1, 2008; 94(8): 1080 - 1088. [Full Text] [PDF] |
||||
![]() |
M. M. Sood, R. P. Pauly, C. Rigatto, and P. Komenda Left ventricular dysfunction in the haemodialysis population NDT Plus, August 1, 2008; 1(4): 199 - 205. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Chonchol, M. Benderly, and U. Goldbourt Beta-blockers for coronary heart disease in chronic kidney disease Nephrol. Dial. Transplant., July 1, 2008; 23(7): 2274 - 2279. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Ritz and C. Wanner The Challenge of Sudden Death in Dialysis Patients Clin. J. Am. Soc. Nephrol., May 1, 2008; 3(3): 920 - 929. [Full Text] [PDF] |
||||
![]() |
K. Toda, K. Taniguchi, H. Matsue, and K. Yoshida Novel adjunct to surgery for end-stage cardiomyopathy receiving hemodialysis Interactive CardioVascular and Thoracic Surgery, April 1, 2008; 7(2): 272 - 274. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Covic, P. Gusbeth-Tatomir, and D. Goldsmith Negative outcome studies in end-stage renal disease: how dark are the storm clouds? Nephrol. Dial. Transplant., January 1, 2008; 23(1): 56 - 61. [Full Text] [PDF] |
||||
![]() |
D. Banerjee, J. Z. Ma, A. J. Collins, and C. A. Herzog Long-Term Survival of Incident Hemodialysis Patients Who Are Hospitalized for Congestive Heart Failure, Pulmonary Edema, or Fluid Overload Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1186 - 1190. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. Khawar, K. Kalantar-Zadeh, W. K. Lo, D. Johnson, and R. Mehrotra Is the Declining Use of Long-Term Peritoneal Dialysis Justified by Outcome Data? Clin. J. Am. Soc. Nephrol., November 1, 2007; 2(6): 1317 - 1328. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Tentori, W. C. Hunt, M. Rohrscheib, M. Zhu, C. A. Stidley, K. Servilla, D. Miskulin, K. B. Meyer, E. J. Bedrick, H. K. Johnson, et al. Which Targets in Clinical Practice Guidelines Are Associated with Improved Survival in a Large Dialysis Organization? J. Am. Soc. Nephrol., August 1, 2007; 18(8): 2377 - 2384. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. H. Pun, R. W. Lehrich, S. R. Smith, and J. P. Middleton Predictors of Survival after Cardiac Arrest in Outpatient Hemodialysis Clinics Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 491 - 500. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Herzog Can We Prevent Sudden Cardiac Death in Dialysis Patients? Clin. J. Am. Soc. Nephrol., May 1, 2007; 2(3): 410 - 412. [Full Text] [PDF] |
||||
![]() |
J. Neumann, G. Ligtenberg, I. H.T. Klein, P. Boer, P. L. Oey, H. A. Koomans, and P. J. Blankestijn Sympathetic Hyperactivity in Hypertensive Chronic Kidney Disease Patients Is Reduced During Standard Treatment Hypertension, March 1, 2007; 49(3): 506 - 510. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Segall and A. Covic Cardiovascular disease in haemodialysis and peritoneal dialysis: arguments pro haemodialysis Nephrol. Dial. Transplant., January 1, 2007; 22(1): 59 - 63. [Full Text] [PDF] |
||||
![]() |
C. A. Herzog Kidney disease in cardiology Nephrol. Dial. Transplant., January 1, 2007; 22(1): 43 - 46. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. W. Lehrich, P. H. Pun, N. D. Tanenbaum, S. R. Smith, and J. P. Middleton Automated External Defibrillators and Survival from Cardiac Arrest in the Outpatient Hemodialysis Clinic J. Am. Soc. Nephrol., January 1, 2007; 18(1): 312 - 320. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. E. Gilbert, K. Connelly, D. J. Kelly, C. A. Pollock, and H. Krum Heart Failure and Nephropathy: Catastrophic and Interrelated Complications of Diabetes Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 193 - 208. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Berl and W. Henrich Kidney-Heart Interactions: Epidemiology, Pathogenesis, and Treatment Clin. J. Am. Soc. Nephrol., January 1, 2006; 1(1): 8 - 18. [Full Text] [PDF] |
||||
![]() |
R. K. Wali, G. S. Wang, S. S. Gottlieb, L. Bellumkonda, R. Hansalia, E. Ramos, C. Drachenberg, J. Papadimitriou, M. A. Brisco, S. Blahut, et al. Effect of kidney transplantation on left ventricular systolic dysfunction and congestive heart failure in patients with end-stage renal disease J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1051 - 1060. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C. Abbott, F. C. Trespalacios, L. Y. Agodoa, A. J. Taylor, and G. L. Bakris {beta}-Blocker Use in Long-term Dialysis Patients: Association With Hospitalized Heart Failure and Mortality Arch Intern Med, December 13, 2004; 164(22): 2465 - 2471. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Neumann, G. Ligtenberg, L. Oey, H. A. Koomans, and P. J. Blankestijn Moxonidine Normalizes Sympathetic Hyperactivity in Patients with Eprosartan-Treated Chronic Renal Failure J. Am. Soc. Nephrol., November 1, 2004; 15(11): 2902 - 2907. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Joles and H. A. Koomans Causes and Consequences of Increased Sympathetic Activity in Renal Disease Hypertension, April 1, 2004; 43(4): 699 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. A. Koomans, P. J. Blankestijn, and J. A. Joles Sympathetic Hyperactivity in Chronic Renal Failure: A Wake-up Call J. Am. Soc. Nephrol., March 1, 2004; 15(3): 524 - 537. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Mallamaci, G. Tripepi, R. Maas, L. Malatino, R. Boger, and C. Zoccali Analysis of the Relationship between Norepinephrine and Asymmetric Dimethyl Arginine Levels among Patients with End-Stage Renal Disease J. Am. Soc. Nephrol., February 1, 2004; 15(2): 435 - 441. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. N. DeMaria, O. Ben-Yehuda, D. Berman, G. K. Feld, B. H. Greenberg, J. D. Knoke, K. U. Knowlton, W. Y. W. Lew, and S. Tsimikas Highlights of the year in JACC 2003 J. Am. Coll. Cardiol., December 17, 2003; 42(12): 2156 - 2166. [Full Text] [PDF] |
||||
![]() |
C. A. Herzog How to Manage the Renal Patient with Coronary Heart Disease: The Agony and the Ecstasy of Opinion-Based Medicine J. Am. Soc. Nephrol., October 1, 2003; 14(10): 2556 - 2572. [Full Text] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |